Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNA GEO-D03
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
DNA GEO-D03 is an investigational DNA plasmid vaccine developed by the National Institute of Allergy and Infectious Diseases (NIAID) for the therapeutic treatment of HIV-1 infection. The vaccine is engineered to co-express HIV-1 virus-like particles (VLPs) containing Gag, Pol, and Env antigens, alongside granulocyte-macrophage colony-stimulating factor (GM-CSF), which serves as a molecular adjuvant to enhance immunogenicity. In clinical development, DNA GEO-D03 is typically utilized as a priming agent in a heterologous prime-boost regimen, followed by a boost with the MVA/HIV62B vaccine. This strategy is intended to stimulate robust cellular and humoral immune responses in HIV-1 infected individuals who are virologically suppressed on highly active antiretroviral therapy (HAART).
- Other names
- GEO-D03 DNA vaccineGEO-D-03 DNA vaccineGEO-D 03 DNA vaccine
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HIV-TCR (HIV-specific T-cell receptor)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on DNA GEO-D03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNA GEO-D03.